These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 21723614

  • 1. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS, Lane SS.
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [Abstract] [Full Text] [Related]

  • 2. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH, Lass JH, Brown GC, Brown MM.
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [Abstract] [Full Text] [Related]

  • 3. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of the Boston keratoprosthesis.
    Ament JD, Stryjewski TP, Ciolino JB, Todani A, Chodosh J, Dohlman CH.
    Am J Ophthalmol; 2010 Feb; 149(2):221-228.e2. PubMed ID: 19939347
    [Abstract] [Full Text] [Related]

  • 5. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG, Brown MM, Brown GC, Sharma S.
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [Abstract] [Full Text] [Related]

  • 6. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC, Brown MM, Turpcu A, Rajput Y.
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [Abstract] [Full Text] [Related]

  • 7. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP, Brown GC, Brown MM.
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [Abstract] [Full Text] [Related]

  • 8. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC, Lade RJ, Adewoyin T, Chong NV.
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [Abstract] [Full Text] [Related]

  • 9. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [Abstract] [Full Text] [Related]

  • 10. Global cost-effectiveness of cataract surgery.
    Lansingh VC, Carter MJ, Martens M.
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [Abstract] [Full Text] [Related]

  • 11. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB, Wittenborn JS, Lee PP, Wirth KE, Sorensen SW, Hoerger TJ, Saaddine JB.
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [Abstract] [Full Text] [Related]

  • 12. Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results.
    Hudson HL, Lane SS, Heier JS, Stulting RD, Singerman L, Lichter PR, Sternberg P, Chang DF, IMT-002 Study Group.
    Ophthalmology; 2006 Nov; 113(11):1987-2001. PubMed ID: 16989902
    [Abstract] [Full Text] [Related]

  • 13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P, De Groote K, Annemans L.
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [Abstract] [Full Text] [Related]

  • 14. Cost utility for penetrating keratoplasty in patients with poor binocular vision.
    Hirneiss C, Neubauer AS, Niedermeier A, Messmer EM, Ulbig M, Kampik A.
    Ophthalmology; 2006 Dec; 113(12):2176-80. PubMed ID: 16996598
    [Abstract] [Full Text] [Related]

  • 15. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome.
    Brown MM, Brown GC, Brown HC, Peet J, Roth Z.
    Arch Ophthalmol; 2009 Feb; 127(2):146-52. PubMed ID: 19204231
    [Abstract] [Full Text] [Related]

  • 16. Cost-utility analysis of cochlear implants in Korea using different measures of utility.
    Lee HY, Park EC, Kim HJ, Choi JY, Kim HN.
    Acta Otolaryngol; 2006 Aug; 126(8):817-23. PubMed ID: 16846923
    [Abstract] [Full Text] [Related]

  • 17. Cataract surgery cost utility revisited in 2012: a new economic paradigm.
    Brown GC, Brown MM, Menezes A, Busbee BG, Lieske HB, Lieske PA.
    Ophthalmology; 2013 Dec; 120(12):2367-2376. PubMed ID: 24246824
    [Abstract] [Full Text] [Related]

  • 18. Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis.
    Brown GC, Brown MM, Chaudhry I, Stein JD.
    JAMA Ophthalmol; 2021 Apr 01; 139(4):389-397. PubMed ID: 33538789
    [Abstract] [Full Text] [Related]

  • 19. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.
    Ophthalmology; 2007 Jun 01; 114(6):1170-8. PubMed ID: 17320964
    [Abstract] [Full Text] [Related]

  • 20. Economic appraisal of the Boston Ocular Surface Prosthesis.
    Shepard DS, Razavi M, Stason WB, Jacobs DS, Suaya JA, Cohen M, Rosenthal P.
    Am J Ophthalmol; 2009 Dec 01; 148(6):860-8.e2. PubMed ID: 19781684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.